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doi:10.1016/j.jfma.2012.01.005Systemic fungal infections have high morbidity and mortality rates in neonates, especially
neonates with an extremely low birth weight (ELBW). Here, we describe a 21-day-old ELBW
female infant with an amphotericin B-unresponsive congenital Candida albicans infection that
was treated with caspofungin. Blood sterilization was performed during the first episode, but
a second episode of candidemia occurred after the discontinuation of caspofungin. Blood ster-
ilization was again performed during the second round of caspofungin treatment, but fungal
endocarditis and renal fungal balls still developed during the second episode. Caspofungin
can be considered for invasive candidiasis in premature infants, especially in life-
threatening situations. As for the focal lesions, more aggressive treatments other than just
parenteral antibiotics should be considered. The literature regarding caspofungin therapy
for neonatal candidiasis is also reviewed.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Neonatal candidemia occurs in 4e15% of extremely low
birth weight infants; the lower the birth weight, the higher
the risk of developing neonatal candidemia.1 Preterm
infants are predisposed to the development of invasivent of Pediatrics, National
hung-Shan S. Road, Taipei,
(C.-Y. Lu).
ight ª 2012, Elsevier Taiwan LLCfungal infections because of their immature mucocuta-
neous barrier and systemic host defenses. Aggressive
neonatal intensive care and prolonged courses of broad-
spectrum antimicrobials are required in such cases.2e4
Candida albicans is the most prevalent pathogen among
the invasive fungal infections that present in neonates
(64e75%).3,5,6 Amphotericin B is often used as an empirical
therapy and is most often the first-line agent for treating
invasive candidiasis in neonates.7 However, despite initial
therapy with amphotericin B, delayed sterilization has been
reported.8& Formosan Medical Association. All rights reserved.
Caspofungin for neonatal candidemia 47Caspofungin is a newly developed echinocandin anti-
fungal agent with proven effectiveness against candidemia
and other invasive Candida infections in adults.9 Caspo-
fungin is a fungicide for treating Candida spp, including
some strains that are resistant to amphotericin B and tri-
azoles.8 According to the updated guidelines published by
the Infectious Diseases Society of America, echinocandins
can be in situations where resistance or toxicity precludes
the use of amphotericin B.10 Recently, clinical trials in
children have shown that caspofungin is well tolerated and
effective in pediatric patients with Candida infections aged
6 months through 17 years.11 However, the use of caspo-
fungin to treat neonates or premature babies is limited.12Case report
A 770-g baby girl was delivered vaginally from a G1P1
mother at 26 weeks of gestation. The mother developed
prematurely ruptured membranes 3 days before delivery
and presented with a fever at delivery. Soon after birth, the
baby suffered from respiratory distress that required intu-
bation, surfactant replacement, and mechanical ventila-
tion. Pneumothorax also presented with unstable vital signs
and required chest tube insertion. Diffuse erythematous
macules and papules, 2e4 mm in diameter, appeared over
the trunk and extremities. Laboratory examinations showedFigure 1 (A) Picture of the infant showing scleroderma and arthro
diffuse desquamation and erosion over the back. (C) Echocardiograp
the right atrium, near the superior vena cava. (D) Renal echocardi
pelvis of the left kidney, with the largest measuring 5.0  4.0 mma leukocyte count of 6,800 cells/mm3 consisting of 24%
segmented neutrophils and 24% banded neutrophils. A
platelet count of 207,000 cells/mm3 and C-reactive protein
(CRP) of 0.6 mg/dL (normal: <0.8 mg/dL) were also noted.
Ampicillin and gentamicin were administered after the
blood cultures were obtained; the patient was then shifted
to vancomycin and ceftazidime on the fifth day due to
progressive hypotension. Meanwhile, scleroderma and
diffuse desquamation with erosions were noted (Fig. 1A and
B). A potassium hydroxide preparation of skin scrapings
showed pseudohyphae; amphotericin B (1 mg/kg/day) was
administrated. Fungal cultures from skin scrapings and
blood were positive for C albicans; meanwhile, the bacte-
rial blood culture was negative. An umbilical arterial and
venous catheter was immediately removed. Due to the
complicated and critical condition of this patient, a central
venous catheter was inserted for vascular access. Minimum
inhibitory concentrations of fluconazole and amphotericin B
were administered at doses of 0.25 and 0.032 mg/mL,
respectively. However, repeated blood cultures that were
taken during the 14 days after amphotericin B therapy were
all positive for C albicans. A cerebral spinal fluid (CSF) study
yielded no evidence of meningitis. No infection focus was
identified by heart, renal, or brain sonography. Ocular
examination did not indicate thrombi or endophthalmitis.
The neonate had persistent thrombocytopenia that
required frequent platelet transfusions and persistentgryposis of both elbows and knees. (B) The skin appears to have
hy showing a highly echogenic mass (4.6  5.0 mm; arrow) over
ogram showing multiple hyperechoic lesions in the calices and
in size (arrow).
Figure 2 RAPD patterns of the eight isolates of C albicans
generated by the four primers: M13, ERIC1, OPA-3, and OPH-15.
Lane M: molecular size markers (1-kb ladder; Gibco BRL,
Gaithersburg, Md.); Lanes 1e8: patterns for isolates 1e8,
respectively. Isolates 1e5 were isolated during the first episode
and isolate 6 was isolated during relapse. Isolates 7 and 8 are
control strains from different patients with candidemia.
48 M.-J. Li et al.hypotension that required inotropic support. On the 21st
day, caspofungin (1.5 mg/kg/day or 13.5 mg/m2/day) was
used to replace amphotericin B. The cumulative dose of
amphotericin B was 11 mg/kg at that time. After 4 days of
caspofungin therapy, the blood culture was negative for C
albicans.
Acute renal failure with hyperkalemia and cholestasis
developed on the 5th and 6th days after caspofungin usage,
respectively; the dose of caspofungin was adjusted to
1 mg/kg/day (9 mg/m2/day). Under the improved and
stable conditions, caspofungin was discontinued for the
total 28-day treatment course, with a total cumulative dose
of 30 mg/kg. Repeated blood and urine cultures were all
negative before caspofungin was discontinued. There was
still no identifiable infection focus by heart, renal, or brain
sonography. Follow-up fundus examination still showed no
thrombi or endophthalmitis.
However, 15 days after the cessation of caspofungin,
candidemia relapsed. This time, the echocardiogram showed
a vegetative mass measuring 4.8 3.5 mm in size in the right
atrium, adjacent to the superior vena cava (Fig. 1C). Renal
ultrasound also showed multiple fungal balls over the calices
and pelvis of both kidneys (Fig. 1D). All isolates were iden-
tified as C albicans by standard biochemical testing using the
API 20C system (API BioMerieux Vitek Inc., Hazelwood, MO,
USA). Genotyping for six isolates of C albicans from this
patient was performed using random, amplified polymorphic
DNA (RAPD) segments using primers M13 (50-GAGGGTGGC
GGTTCT-30), ERIC1 (50-GTGAATCCCCAGGAGCTTACAT30),13
OPA3 (50-AGTCAGCCAC-30),14 and OPH-15 (50-AATGGCG
CAG-30) (Operon Technologies, Inc., Alameda, CA, USA). The
results show that the C albicans samples isolated during
the relapse were the same strain as the earlier isolates
(Fig. 2). A whole body survey showed that there were no
brain abscesses, ventriculitis, meningitis, or endoph-
thalmitis. Caspofungin was administrated again and blood
sterilization was achieved 4 days later. Additional blood
cultures all revealed negative results. Follow-up cardiac and
renal echocardiograms showed that the vegetation persisted
while the renal fungal balls had resolved to stone formations.
Unfortunately, the general condition of this patient
progressively deteriorated thereafter. Episodes of sepsis
were suspected but not documented. The neonate finally
passed away at the age of 128 days due to multiple organ
failure.Discussion
Congenital Candida infections produce a wide spectrum of
symptoms, ranging from diffuse skin eruptions to severe
systemic disease resulting in fetal demise or early neonatal
death.12 Diffuse skin rash was the most striking clinical
manifestation in our case, which led to a strong suspicion of
neonatal candidiasis.
Amphotericin B is often used empirically as a first-line
agent to treat invasive candidiasis in neonates.7,10 We
initially used 1 mg/kg/day amphotericin B, as recom-
mended.15 Unfortunately, the patient did not show any
improvement, and persistent candidemia and clinical dete-
riorationmanifested. Thus, we replaced amphotericin B with
caspofungin, which has been reported as effective forcontrolling neonatal candidemia refractory to amphotericin
B therapy9,16 and as a possible salvage therapy.10,17,18
However, the use of caspofungin to treat preterm babies is
limited. We reviewed reports on caspofungin usage in
preterm babies with Candida infections as far back as 2003.
In addition to our patient, 27 cases in the medical literature
that included clinical data were found using a MEDLINE
search (Table 1). All but three of these cases achieved blood
sterilization using caspofungin. Focal infection foci, such as
heart vegetation or renal fungal balls, were found in all cases
that failed to respond to caspofungin treatment. The time
periods needed to achieve blood sterilization varied
between 1e21 days, but 3e7 days was typical. Five cases
that achieved blood sterilization experienced a relapse of
candidemia within 2e60 days after the discontinuation of
caspofungin. Most of the relapsed cases (4 in 5) developed
a focal fungal infection.
In our case, caspofungin indeed successfully controlled
candidemia, which was unresponsive to amphotericin B
treatment. The relapse of candidemia after the discontin-
uation of caspofungin was most likely due to the existence
of undetectable infection foci in the heart and/or kidneys.
The early use of antifungal agents might minimize the
chances of disseminated lodged Candida infections from
the bloodstream by preventing persistent candidemia. In
Table 1 Summary of reports in the medical literature on the use of caspofungin therapy to treat 28 preterm babies with Candida infections.
Author Year Cases
(no.)
Gestational age
(GA) (wk)
Birth body
weight (g)
Isolate Site Dose of caspofungin Outcome Time to
sterilization
Hesseling
et al17
2003 1 24 Not available C. guilliermondii Blood, heart Loading dose of 50 mg/m2,
then 35 mg/m2/day for 7 days
Failure, death Not applicable
Odio et al8 2004 10 31e37 1150e2610
(median: 1495)
4 C. albicans
3 C. parapsilosis
2 C. tropicalis
1 C. glabrata
10 blood,
1 heart
1 CSF, urine,
kidney
1 case: 0.5 mg/kg/day for 3
days, then 1 mg/kg/day for 28
days
Other cases: 1 mg/kg/day for
2 days, then 2 mg/kg/day for
15e21days
10 sterilized,
1 relapsed,
1 death
Mean: 4.3 days
Natarajan G
et al15
2005 13 12 preterm
(24e28wk), 1
full-term
530-5600
(median 800)
5 C. albicans
6 C. parapsilosis
1 C. albicans þ
C. parapsilosis
1 C. tropicalis
13 blood,
8 kidney,
3 heart,
2 lung,
2 CSF,
3 skin
1 mg/kg/day
5 cases: loading dose of
1.5 mg/kg.
(All cases combined with other
conventional antifungal agents)
11 sterilized,
3 relapsed,
7 deaths
Median: 3 days
(range: 1e21days)
Manzar S et al18 2006 1 23 660 C. glabrata Blood Not available Sterilized,
survived
3 days
Yalaz M et al11 2006 1 27 980 C. parapsilosis Blood 5 mg/kg/day for 3 days, then
2.5 mg/kg/day (total
treatment: 21days)
Sterilized,
survive
7 days
Smith et al 2007 1 25 810 C. albicans Blood, urine,
kidney
Loading dose: 100 mg/m2
(8 mg/kg), then 70 mg/m2/day
(6 mg/kg/day)
Sterilized,
survived
8 days
Present case 2008 1 26 770 C. albicans Blood, heart,
kidney, skin
1-1.5 mg/kg/day Sterilized, but
relapsed
and died
4 days, relapse 15 days
after discontinuing
of treatment
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50 M.-J. Li et al.addition to early treatment, a sufficiently long treatment
duration is also important for preventing disseminated
Candida infections. Currently, the recommended length
of therapy for candidemia is 3 weeks.10 This patient was
treated for a longer period of time that may be necessary,
at least for cases with risk factors. Premature infants are at
special risk because they have immature organ functions,
poor immune responses, and prolonged hospitalization that
is usually accompanied by a broad spectrum of antibiotics
and invasive equipment. Furthermore, candidiasis may not
be totally eradicated by antifungal treatment but only
temporarily suppressed. Candidiasis may manifest again in
high-risk hosts, especially in those with compromised
immune systems. Regular and careful examinations that
can detect infection foci before and after the discontinu-
ation of antifungal therapy are warranted in cases with
persistent candidemia. The failure to cure our patient in
the second episode demonstrates the fact that antifungal
agents are probably insufficient to cure focal infection foci
due to poor penetrations into the vegetations or fungal
balls. Once an infection focus has developed, elimination of
the focus by surgical intervention should be considered.
The optimal dose of caspofungin in premature babies
remains uncertain. Nilgun et al used a dose of 5 mg/kg/day
(50 mg/m2/day) for 3 days, followed by 2.5 mg/kg/day
(25 mg/m2/day).12 Walsh et al reported an initial caspo-
fungin dosage of 1 mg/kg/day (9e14.5 mg/m2/day) for 2
days followed by 2 mg/kg/day (18e29 mg/m2/day) for
15e21 days.7 We used 1.5 mg/kg/day (13.5 mg/m2/day) to
treat the first candidemia episode, and blood sterilization
was rapidly achieved on the 4th day. During the second
candidemia episode, we adjusted the dose to 1 mg/kg/day
(9 mg/m2/day) due to impaired liver and renal functions.
Sterilization was achieved after 4 days of caspofungin
usage. For severe infections, higher dosages might lead to
earlier sterilization and should be used under close
surveillance due to potentially adverse effects.
In conclusion, disseminated neonatal candidiasis is
a clinical challenge for physicians. Early detection, evalu-
ation of the involvement of the systemic organs, and
effective treatment are key to the successful treatment of
neonatal candidiasis. Caspofungin is a new antifungal and is
effective for invasive neonatal candidemia, especially in
those that respond poorly to conventional antifungal drugs.
Earlier intervention with higher or prolonged usage of cas-
pofungin should be considered for complicated or critical
cases. However, relapse after caspofungin therapy can
occur and should be carefully monitored. Invasive candi-
diasis in neonates, especially in premature babies, should
be considered early, treated seriously and completely, and
carefully monitored.Funding
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